2023 World Conference on Lung Cancer (Posters)-EP09.02. A Phase II Study on Aggressive Local Consolidative Therapy in Combination With Chemotherapy for Oligometastic NSCLC: TORG1529

EP09.02. A Phase II Study on Aggressive Local Consolidative Therapy in Combination With Chemotherapy for Oligometastic NSCLC: TORG1529 - PDF(Abstract)

Back to course

Pdf Summary

A phase II study was conducted to evaluate the efficacy and safety of aggressive local consolidative therapy (LCT) in combination with chemotherapy for patients with oligometastatic non-small cell lung cancer (NSCLC). The study included 19 patients with Stage IV NSCLC and oligometastases, who underwent chemoradiotherapy (CRT) for thoracic disease and LCT for oligometastases. The primary endpoint of the study was the 2-year survival rate.<br /><br />The results showed that all patients completed CRT concurrently with LCT for all oligometastases. A response rate of 58% (based on 11 partial responses) was observed. Median progression-free survival and overall survival were 8.6 and 42.1 months, respectively. The 2-year survival rate was 68.4%. Fourteen patients showed progression with newly observed lesions. No severe adverse events were reported, and toxicities were tolerable.<br /><br />The study suggests that chemotherapy in combination with aggressive LCT for NSCLC with oligometastases may extend survival and achieve local control. The findings indicate that radical treatment can potentially cure Stage IV NSCLC with oligometastases.<br /><br />The study emphasizes the importance of integrating local therapies with systemic therapies for the treatment of metastatic NSCLC. The use of LCT in combination with standard chemoradiotherapy improves response rates and extends survival in patients with oligometastatic NSCLC.<br /><br />This study provides evidence for the efficacy and safety of aggressive local consolidative therapy in combination with chemotherapy for patients with oligometastatic NSCLC. The findings suggest that this treatment approach can be considered as a potential curative option for select patients with oligometastatic NSCLC. Further research and larger trials are needed to validate these findings and optimize treatment strategies for this patient population.

Asset Subtitle

Takaaki Tokito

Meta Tag

Speaker Takaaki Tokito

Topic Metastatic NSCLC: Local Therapies - Integration With Systemic Therapies

Keywords

aggressive local consolidative therapy

chemotherapy

oligometastatic non-small cell lung cancer

NSCLC

chemoradiotherapy

2-year survival rate

response rate

progression-free survival

metastatic NSCLC

curative option